Program
zilebesiran
Also written as “Zilebesiran” and “ALN-AGT01”.
Its studies are mostly in Hypertension, led by Alnylam Pharmaceuticals.
Furthest: phase 3, since Sep 12, 20255 company-led studies, 1 open or runningNext primary completion: Sep 23, 2030 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alnylam Pharmaceuticals | 51 open or running | phase 3since Sep 12, 2025 | Apr 29, 2019 | Sep 23, 2030phase 3 · NCT07181109 |
- Named in hoffmann la roche’s own pipeline as
RG6615 zilebesiran (Alnylam)
, phase 3, as of Oct 22, 2026 (source).
Also a collaborator on its studies: Hoffmann-La Roche.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 29, 2019First study: phase 1 study in HypertensionFirst studyNCT03934307 · 124 enrolled · United Kingdom
- Jun 14, 2021Phase 2 study in HypertensionNCT04936035 · 394 enrolled · United States, Canada, Puerto Rico and more
- Feb 15, 2024Phase 2 study in HypertensionNCT06272487 · 375 enrolled · United States, Australia, Canada and more
- May 15, 2024Phase 2 study in HypertensionNCT06423352 · 36 enrolled · Japan
- Sep 12, 2025Phase 3 study in HypertensionNCT07181109 · 11,000 planned · United States, Argentina, Australia and more
Ahead
- Sep 23, 2030Primary completion: phase 3 study in HypertensionNCT07181109
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07181109Hypertension · United States, Argentina, Australia and more | 3 | Recruiting | Sep 23, 2030 | 11,000 |
| NCT06423352Hypertension · Japan | 2 | Completed | Jul 17, 2025 | 36 |
| NCT06272487Hypertension · United States, Australia, Canada and more | 2 | Completed | Jun 19, 2025 | 375 |
| NCT04936035Hypertension · United States, Canada, Puerto Rico and more | 2 | Completed | Apr 4, 2023 | 394 |
| NCT03934307Hypertension · United Kingdom | 1 | Completed | Apr 20, 2022 | 124 |
How it is read
Names in the registry
- “Zilebesiran”, 3 entries
- “ALN-AGT01”, 2 entries
Conditions, from the studies’ own filings
- Hypertension, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.